Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 7Phase 1 7Phase 3 4

Status

Completed 4Withdrawn 1

Sponsor Class

NIH 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Melanoma 2Skin Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Completed × oblimersen × Clear all
NCT00016263 2014-01-06

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

National Cancer Institute (NCI)

Phase 3 Completed
Dermatologic

Melanoma

NCT00017602 2014-01-06

Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Completed
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00024440 2014-01-06

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00518895 2011-11-07

AGENDA

Genta Incorporated

Phase 3 Completed
300 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡